SIMVASTATIN - simvastatin tablet, film coated State of Florida DOH Central Pharmacy

HIGHLIGHTS OF PRESCRIBING INFOR	MATION
	nformation needed to use simvastatin safely and effectively. See full
	- RECENT MAJOR CHANGES ·····
Dosage and Administration Coadministration with Other Drugs (2.3) Contraindications (4) Warnings and Precautions	10/2012 10/2012
Myopathy/Rhabdomyolysis (5.1)	10/2012
Simvastatin is an HMG-CoA reductase inhibit • Reduce the risk of total mortality by reduci and the need for revascularization procedure • Reduce elevated total-C, LDL-C, Apo B, TC familial and nonfamilial) and mixed dyslipider • Reduce elevated TG in patients with hype lipoproteinemia. (1.2) (1) • Reduce total-C and LDL-C in adult patients	rtriglyceridemia and reduce TG and VLDL-C in patients with primary dysbeta- with homozygous familial hypercholesterolemia. (1.2) (1) in boys and postmenarchal girls, 10 to 17 years of age with heterozygous
Simvastatin has not been studied in Fredricks	son Types Land V dyslinidemias (14)(1)
	OSAGE AND ADMINISTRATION
 Dose range is 5 to 40 mg/day. (2.1) (2) Recommended usual starting dose is 10 or Recommended starting dose for patients at Due to the increased risk of myopathy, inchrestricted to patients who have been taking of muscle toxicity. (2.2) (2) Patients who are currently tolerating the 80 contraindicated or is associated with a dose of for the drug-drug interaction. (2.2) (2) Due to the increased risk of myopathy, inchreated to achieve their LDL-C goal utilizing the should be placed on alternative LDL-C-lower Adolescents (10-17 years of age) with HeFF (2.5) (2) 	20 mg once a day in the evening. (2.1) (2) thigh risk of CHD is 40 mg/day. (2.1) (2) uding rhabdomyolysis, use of the 80-mg dose of simvastatin should be simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence -mg dose of simvastatin who need to be initiated on an interacting drug that is tap for simvastatin should be switched to an alternative statin with less potential uding rhabdomyolysis, associated with the 80-mg dose of simvastatin, patients the 40-mg dose of simvastatin should not be titrated to the 80-mg dose, but ering treatment(s) that provides greater LDL-C lowering. (2.2) (2) H starting dose is 10 mg/day; maximum recommended dose is 40 mg/day.
Tablets: 5 mg; 10 mg; 20 mg; 40 mg; 80 mg	
 Concomitant administration of strong CYP3 Concomitant administration of gemfibrozil, Hypersensitivity to any component of this m Active liver disease, which may include une Women who are pregnant or may become p Nursing mothers. (4, 8.3) (4) 	cyclosporine, or danazol. (4, 5.1) (4) nedication. (4, 6.2) (4) explained persistent elevations in hepatic transaminase levels. (4, 5.2) (4) pregnant. (4, 8.1) (4)
	VARNINGS AND PRECAUTIONS
(5.1) (5)Skeletal muscle effects (e.g., myopathy and	ased risk of myopathy including rhabdomyolysis with the 80-mg dose. I rhabdomyolysis): Risks increase with higher doses and concomitant use of de advanced age (≥65), female gender, uncontrolled hypothyroidism, and

• Patients should be advised to report promptly any unexplained and/or persistent muscle pain, tenderness, or weakness. Simvastatin therapy should be discontinued immediately if myopathy is diagnosed or suspected. See Drug Interaction

table. (5.1) (5)

• Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. (5.2) (5)

Most common adverse reactions (incidence ≥5.0%) are: upper respiratory infection, headache, abdominal pain, constipation, and nausea. (6.1) (6)

To report SUSPECTED ADVERSE REACTIONS, contact Blu Pharmaceuticals at 1-877-264-0258 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

Interacting Agents	Prescribing Recommendations
Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone), gemfibozil, cyclosporine, danazol (7)	Contraindicated with simvastatin
Verapamil, diltiazem, dronedarone	Do not exceed 10 mg simvastatin daily
Amiodarone, amlodipine, ranolazine	Do not exceed 20 mg simvastatin daily
Grape fruit juice	Avoid grapefruit juice

• Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (≥ 1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with simvastatin. (5.1, 7.2, 7.4) (7)

• Coumarin anticoagulants: Concomitant use with simvastatin prolongs INR. Achieve stable INR prior to starting simvastatin. Monitor INR frequently until stable upon initiation or alteration of simvastatin therapy. (7.6) (7)

• Severe renal impairment: patients should be started at 5 mg/day and be closely monitored. (2.6, 8.6) (8)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 1/2015

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE

1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events

1.2 Hyperlipidemia

1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

1.4 Limitations of Use

2.1 Recommended Dosing

2.2 Restricted Dosing for 80 mg

2.3 Coadministration with Other Drugs

2.4 Patients with Homozygous Familial Hypercholesterolemia

2.5 Adolescents (10-17 years of age) with Heterozygous Familial Hypercholesterolemia

2.6 Patients with Renal Impairment

2.7 Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of Niacin-Containing Products

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5.1 Myopathy/Rhabdomyolysis

- 5.2 Liver Dysfunction
- 5.3 Endocrine Function
- 6.1 Clinical Trials Experience

- 6.2 Post-Marketing Experience
- 7.1 Strong CYP3A4 Inhibitors, cyclosporine, or danazol
- 7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone
- 7.3 Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers
- 7.4 Niacin
- 7.5 Digoxin
- 7.6 Coumarin Anticoagulants
- 7.7 Colchicine
- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- **10 OVERDOSAGE**

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Clinical Studies in Adults
- 14.2 Clinical Studies in Adolescents

16 HOW SUPPLIED

17 PATIENT COUNSELING INFORMATION

- 17.1 Muscle Pain
- 17.2 Liver Enzymes
- 17.3 Pregnancy
- 17.4 Breastfeeding
- * Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet.

1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events

In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin is indicated to:

- Reduce the risk of total mortality by reducing CHD deaths.
- Reduce the risk of non-fatal myocardial infarction and stroke.
- Reduce the need for coronary and non-coronary revascularization procedures.

1.2 Hyperlipidemia

Simvastatin is indicated to:

• Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb).

- Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia).
- Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type lll hyperlipidemia).

• Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.

1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

Simvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present:

- 1. LDL cholesterol remains \geq 190 mg/dL; or
- 2. LDL cholesterol remains $\geq 160 \text{ mg/dL}$ and
- There is a positive family history of premature cardiovascular disease (CVD) or
- Two or more other CVD risk factors are present in the adolescent patient.

The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C

<130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined.

1.4 Limitations of Use

Simvastatin has not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).

2.1 Recommended Dosing

The usual dosage range is 5 to 40 mg/day. In patients with CHD or at high risk of CHD, simvastatin can be started simultaneously with diet. The recommended usual starting dose is 10 or 20 mg once a day in the evening. For patients at high risk for a CHD event due to existing CHD, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, the recommended starting dose is 40 mg/day. Lipid determinations should be performed after 4 weeks of therapy and periodically thereafter.

2.2 Restricted Dosing for 80 mg

Due to the increased risk of myopathy, including rhabdomyolysis, particularly during the first year of treatment, use of the 80-mg dose of simvastatin should be restricted to patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see **Warnings and Precautions (5.1)**].

Patients who are currently tolerating the 80-mg dose of simvastatin who need to be initiated on an

interacting drug that is contraindicated or is associated with a dose cap for simvastatin should be switched to an alternative statin with less potential for the drug-drug interaction.

Due to the increased risk of myopathy, including rhabdomyolysis, associated with the 80-mg dose of simvastatin, patients unable to achieve their LDL-C goal utilizing the 40-mg dose of simvastatin should not be titrated to the 80-mg dose, but should be placed on alternative LDL-C-lowering treatment(s) that provides greater LDL-C lowering.

2.3 Coadminis tration with Other Drugs

Patients taking Verapamil, Diltiazem, or Dronedarone

• The dose of simvastatin should not exceed 10 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)].

Patients taking Amiodarone, Amlodipine or Ranolazine.

• The dose of simvastatin should not exceed 20 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)].

2.4 Patients with Homozygous Familial Hypercholes terolemia

The recommended dosage is 40 mg/day in the evening [see Dosage and Administration, Restricted Dosing for 80 mg (2.2)]. Simvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

2.5 Adolescents (10-17 years of age) with Heterozygous Familial Hypercholesterolemia

The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10 to 40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy [see NCEP Pediatric Panel Guidelines¹ and Clinical Studies (14.2)]. Adjustments should be made at intervals of 4 weeks or more.

¹ National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 89(3):495-501. 1992.

2.6 Patients with Renal Impairment

Because simvastatin does not undergo significant renal excretion, modification of dosage should not be necessary in patients with mild to moderate renal impairment. However, caution should be exercised when simvastatin is administered to patients with severe renal impairment; such patients should be started at 5 mg/day and be closely monitored [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

2.7 Chinese Patients Taking Lipid-Modifying Doses (≥1 g/day Niacin) of Niacin-Containing Products

Because of an increased risk for myopathy in Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses (≥ 1 g/day niacin) of niacin-containing products, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for myopathy is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products. The cause of the increased risk of myopathy is not known. It is also unknown if the risk for myopathy with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients. [See Warnings and Precautions (5.1).]

3 DOSAGE FORMS AND STRENGTHS

• Tablets simvastatin 5 mg are white to off white, oval, biconvex, film-coated tablets with "B300" debossed on one side and "5" on the other side.

• Tablets simvastatin 10 mg are peach to dark peach, oval, biconvex, film-coated tablets with "B301" debossed on one side and "10" on the other side.

• Tablets simvastatin 20 mg are orange to dark orange, oval, biconvex, film-coated tablets with "B302" debossed on one side and "20" on the other side.

• Tablets simvastatin 40 mg are light pink to pink, oval, biconvex, film-coated tablets with "B303" debossed on one side and "40" on the other side.

• Simvastatin Tablets USP 80 mg are dark pink to pink, capsule-shaped, film-coated tablets with "B304" debossed on one side and "80" on the other side.

4 CONTRAINDICATIONS

Simvastatin is contraindicated in the following conditions:

• Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone) [see Warnings and Precautions (5.1)].

• Concomitant administration of gemfibrozil, cyclosporine, or danazol [see Warnings and Precautions (5.1)].

• Hypersensitivity to any component of this medication [see Adverse Reactions (6.2)].

• Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels [see Warnings and Precautions (5.2)].

• Women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins) decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, simvastatin may cause fetal harm when administered to a pregnant woman. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of use with simvastatin during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of teratogenicity. **Simvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive.** If the patient becomes pregnant while taking this drug, simvastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)].

• Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require treatment with simvastatin should not breastfeed their infants [see Use in Specific Populations (8.3)].

5.1 Myopathy/Rhabdomyolysis

Simvastatin, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is increased by high levels of statin activity in plasma. Predisposing factors for myopathy include advanced age (≥ 65 years), female gender, uncontrolled

hypothyroidism, and renal impairment.

The risk of myopathy, including rhabdomyolysis, is dose related. In a clinical trial database in which 41,413 patients were treated with simvastatin, 24,747 (approximately 60%) of whom were enrolled in studies with a median follow-up of at least 4 years, the incidence of myopathy was approximately 0.03% and 0.08% at 20 and 40 mg/day, respectively. The incidence of myopathy with 80 mg (0.61%) was disproportionately higher than that observed at the lower doses. In these trials, patients were carefully monitored and some interacting medicinal products were excluded.

In a clinical trial in which 12,064 patients with a history of myocardial infarction were treated with simvastatin (mean follow-up 6.7 years), the incidence of myopathy (defined as unexplained muscle weakness or pain with a serum creatine kinase [CK] >10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of rhabdomyolysis (defined as myopathy with a CK >40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of myopathy, including rhabdomyolysis, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded.

The risk of myopathy, including rhabdomyolysis, is greater in patients on simvastatin 80 mg compared with other statin therapies with similar or greater LDL-C-lowering efficacy and compared with lower doses of simvastatin. Therefore, the 80-mg dose of simvastatin should be used only in patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Dosage and Administration, Restricted Dosing for 80 mg (2.2)]. If, however, a patient who is currently tolerating the 80-mg dose of simvastatin needs to be initiated on an interacting drug that is contraindicated or is associated with a dose cap for simvastatin, that patient should be switched to an alternative statin with less potential for the drug-drug interaction. Patients should be advised of the increased risk of myopathy, including rhabdomyolysis, and to report promptly any unexplained muscle pain, tenderness or weakness. If symptoms occur, treatment should be discontinued immediately. [See Warnings and Precautions (5.2).]

There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.

All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, should be advised of the risk of myopathy, including rhabdomyolysis, and told to report promptly any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing simvastatin. Simvastatin therapy should be discontinued immediately if myopathy is diagnosed or suspected. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued. Periodic CK determinations may be considered in patients starting therapy with simvastatin or whose dose is being increased, but there is no assurance that such monitoring will prevent myopathy.

Many of the patients who have developed rhabdomyolysis on therapy with simvastatin have had complicated medical histories, including renal insufficiency usually as a consequence of long-standing diabetes mellitus. Such patients merit closer monitoring. Simvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Simvastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis, hypotension; major surgery; trauma; severe metabolic endocrine, or electrolyte disorders; or uncontrolled epilepsy.

Drug Interactions

The risk of myopathy and rhabdomyolysis is increased by high levels of statin activity in plasma. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs which inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of myopathy. These include itraconazole, ketoconazole, and posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or grapefruit juice [see Clinical Pharmacology (12.3)]. Combination of these drugs with simvastatin is contraindicated. If short-term treatment with strong CYP3A4 inhibitors is unavoidable, therapy with simvastatin must be suspended during the course of treatment. [See Contraindications (4) and Drug Interactions (7.1).]

The combined use of simvastatin with gemfibrozil, cyclosporine, or danazol is contraindicated [see Contraindications (4) and Drug Interactions (7.1 and 7.2)].

Caution should be used when prescribing other fibrates with simvastatin, as these agents can cause myopathy when given alone and the risk is increased when they are co-administered [see Drug Interactions (7.2)].

Cases of myopathy, including rhabdomyolysis, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine [see Drug Interactions (7.7)].

The benefits of the combined use of simvastatin with the following drugs should be carefully weighed against the potential risks of combinations: other lipid-lowering drugs (other fibrates or ≥ 1 g/day of niacin), amiodarone, dronedarone, verapamil, diltiazem, amlodipine, or ranolazine [see Drug Interactions (7.3) and Table 3 in Clinical Pharmacology (12.3)].

Cases of myopathy, including rhabdomyolysis, have been observed with simvastatin coadministered with lipid-modifying doses (≥ 1 g/day niacin) of niacin-containing products. In an ongoing, double-blind, randomized cardiovascular outcomes trial, an independent safety monitoring committee identified that the incidence of myopathy is higher in Chinese compared with non-Chinese patients taking simvastatin 40 mg coadministered with lipid-modifying doses of a niacin-containing product. Caution should be used when treating Chinese patients with simvastatin in doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for myopathy is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products. It is unknown if the risk for myopathy with coadministration of simvastatin with lipid-modifying doses of niacin-containing products observed in Chinese patients applies to other Asian patients [see Drug Interactions (7.4)].

Prescribing recommendations for interacting agents are summarized in Table 1 [see also Dosage and Administration (2.3), Drug Interactions (7), Clinical Pharmacology (12.3)].

Interacting Agents	Prescribing Recommendations
Strong CYP3A4 Inhibitors, e.g.: Itraconazole Ketoconazole Posaconazole Voriconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Boceprevir Telaprevir Nefazodone Gemfibrozil Cyclosporine Danazol	Contraindicated with simvastatin
Verapamil Diltiazem Dronedarone	Do not exceed 10 mg simvastatin daily
Amiodarone Amlodipine Ranolazine	Do not exceed 20 mg simvastatin daily
Grapefruit juice	Avoid grapefruit juice

TABLE 1 Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis

5.2 Liver Dysfunction

Persistent increases (to more than 3X the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. There was no evidence of hypersensitivity.

In the Scandinavian Simvastatin Survival Study (4S) [see Clinical Studies (14.1)], the number of patients with more than one transaminase elevation to >3X ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). Elevated transaminases resulted in the discontinuation of 8 patients from therapy in the simvastatin group (n=2,221) and 5 in the placebo group (n=2,223). Of the 1,986 simvastatin treated patients in 4S with normal liver function tests (LFTs) at baseline, 8 (0.4%) developed consecutive LFT elevations to >3X ULN and/or were discontinued due to transaminase elevations during the 5.4 years (median follow-up) of the study. Among these 8 patients, 5 initially developed these abnormalities within the first year. All of the patients in this study received a starting dose of 20 mg of simvastatin; 37% were titrated to 40 mg.

In 2 controlled clinical studies in 1,105 patients, the 12-month incidence of persistent hepatic transaminase elevation without regard to drug relationship was 0.9% and 2.1% at the 40- and 80-mg dose, respectively. No patients developed persistent liver function abnormalities following the initial 6 months of treatment at a given dose.

It is recommended that liver function tests be performed before the initiation of treatment, and thereafter when clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including simvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with simvastatin, promptly interrupt therapy. If an alternate etiology is not found do not restart simvastatin. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate myopathy [see Warnings and Precautions (5.1)].

The drug should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained transaminase elevations are contraindications to the use of simvastatin.

As with other lipid-lowering agents, moderate (less than 3X ULN) elevations of serum transaminases have been reported following therapy with simvastatin. These changes appeared soon after initiation of therapy with simvastatin, were often transient, were not accompanied by any symptoms and did not require interruption of treatment.

5.3 Endocrine Function

Increases in $\rm HbA1_{c}$ and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including simvastatin.

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

In the pre-marketing controlled clinical studies and their open extensions (2,423 patients with median duration of follow-up of approximately 18 months), 1.4% of patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%). The most commonly reported adverse reactions (incidence \geq 5%) in simvastatin controlled clinical trials were: upper respiratory infections (9.0%), headache (7.4%), abdominal pain (7.3%), constipation (6.6%), and nausea (5.4%).

Scandinavian Simvastatin Survival Study

In 4S involving 4,444 (age range 35-71 years, 19% women, 100% Caucasians) treated with 20-40 mg/day of simvastatin (n=2,221) or placebo (n=2,223) over a median of 5.4 years, adverse reactions reported in \geq 2% of patients and at a rate greater than placebo are shown in Table 2.

	Simvastatin (N = 2,221) %	Placebo (N = 2,223) %
Body as a Whole		
Edema/swelling	2.7	2.3
Abdominal pain	5.9	5.8
Cardiovascular System Disorders		
Atrial fibrillation	5.7	5.1
Digestive System Disorders		
Constipation	2.2	1.6
Gastritis	4.9	3.9
Endocrine Disorders		
Diabetes mellitus	4.2	3.6
Musculoskeletal Disorders		
Myalgia	3.7	3.2
Nervous System/ Psychiatric		
Disorders		
Headache	2.5	2.1
Insomnia	4.0	3.8
Vertigo	4.5	4.2
Respiratory System Disorders		
Bronchitis	6.6	6.3
Sinusitis	2.3	1.8
Skin / Skin Appendage Disorders	2.0	
Eczema	4.5	3.0
Urogenital System Disorders	4.0	0.0
Infection, urinary tract	3.2	3.1

Heart Protection Study

In the Heart Protection Study (HPS), involving 20,536 patients (age range 40-80 years, 25% women, 97% Caucasians, 3% other races) treated with simvastatin 40 mg/day (n=10,269) or placebo (n=10,267) over a mean of 5 years, only serious adverse reactions and discontinuations due to any adverse reactions were recorded. Discontinuation rates due to adverse reactions were 4.8% in patients treated with simvastatin compared with 5.1% in patients treated with placebo. The incidence of myopathy/rhabdomyolysis was <0.1% in patients treated with simvastatin.

Other Clinical Studies

In a clinical trial in which 12,064 patients with a history of myocardial infarction were treated with simvastatin (mean follow-up 6.7 years), the incidence of myopathy (defined as unexplained muscle weakness or pain with a serum creatine kinase [CK] >10 times upper limit of normal [ULN]) in patients on 80 mg/day was approximately 0.9% compared with 0.02% for patients on 20 mg/day. The incidence of rhabdomyolysis (defined as myopathy with a CK >40 times ULN) in patients on 80 mg/day was approximately 0.4% compared with 0% for patients on 20 mg/day. The incidence of myopathy, including rhabdomyolysis, was highest during the first year and then notably decreased during the subsequent years of treatment. In this trial, patients were carefully monitored and some interacting medicinal products were excluded.

Other adverse reactions reported in clinical trials were: diarrhea, rash, dyspepsia, flatulence, and asthenia.

Laboratory Tests

Marked persistent increases of hepatic transaminases have been noted [see Warnings and Precautions (5.2)]. Elevated alkaline phosphatase and γ -glutamyl transpeptidase have also been reported. About 5% of patients had elevations of CK levels of 3 or more times the normal value on one or more occasions. This was attributable to the noncardiac fraction of CK. [See Warnings and Precautions (5.1).]

Adolescent Patients (ages 10-17 years)

In a 48-week, controlled study in adolescent boys and girls who were at least 1 year post-menarche, 10-17 years of age (43.4% female, 97.7% Caucasians, 1.7% Hispanics, 0.6% Multiracial) with heterozygous familial hypercholesterolemia (n=175), treated with placebo or simvastatin (10-40 mg daily), the most common adverse reactions observed in both groups were upper respiratory infection, headache, abdominal pain, and nausea [see Use in Specific Populations (8.4) and Clinical Studies (14.2)].

6.2 Post-Marketing Experience

Because the below reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during postapproval use of simvastatin: pruritus, alopecia, a variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails), dizziness, muscle cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting, anemia, erectile dysfunction, interstitial lung disease, rhabdomyolysis, hepatitis/jaundice, fatal and non-fatal hepatic failure, and depression.

There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see *Warnings and Precautions* (5.1)].

An apparent hypersensitivity syndrome has been reported rarely which has included some of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable time to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

7.1 Strong CYP3A4 Inhibitors, cyclosporine, or danazol

Strong CYP3A4 inhibitors: Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.

Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.

Cyclosporine or danazol: The risk of myopathy, including rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol. Therefore, concomitant use of these drugs is contraindicated. [see Contraindications (4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone

Gemfibrozil: Contraindicated with simvastatin [see Contraindications (4) and Warnings and Precautions (5.1)].

Other fibrates: Caution should be used when prescribing with simvastatin [see Warnings and Precautions (5.1)].

7.3 Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers

The risk of myopathy, including rhabdomyolysis is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem or amlodipine [see Dosage and Administration (2.3) and Warnings and Precautions (5.1), and Table 3 in Clinical Pharmacology (12.3)].

7.4 Niacin

Cases of myopathy/rhabdomyolysis have been observed with simvastatin coadministered with lipidmodifying doses (≥ 1 g/day niacin) of niacin-containing products. In particular, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipidmodifying doses of niacin-containing products. Because the risk for myopathy is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacincontaining products. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]

7.5 Digoxin

In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].

7.6 Coumarin Anticoagulants

In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy

has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.

7.7 Colchicine

Case of myopathy, including rhabdomyolysis, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine.

8.1 Pregnancy

Pregnancy Category X [See Contraindications (4).]

Sinvastatin is contraindicated in women who are or may become pregnant. Lipid lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. There are no adequate and well-controlled studies of use with simvastatin during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins in utero. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of teratogenicity. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Because statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, simvastatin may cause fetal harm when administered to a pregnant woman. If simvastatin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

There are rare reports of congenital anomalies following intrauterine exposure to statins. In a review² of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally related statin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed those expected in the general population. However, the study was only able to exclude a 3- to 4-fold increased risk of congenital anomalies over the background rate. In 89% of these cases, drug treatment was initiated prior to pregnancy and was discontinued during the first trimester when pregnancy was identified.

Women of childbearing potential, who require treatment with simvastatin for a lipid disorder, should be advised to use effective contraception. For women trying to conceive, discontinuation of simvastatin should be considered. If pregnancy occurs, simvastatin should be immediately discontinued.

8.3 Nursing Mothers

It is not known whether simvastatin is excreted in human milk. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother [see Contraindications (4)].

8.4 Pediatric Use

² Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Post marketing Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy, Reproductive Toxicology, 10(6):439-446, 1996.

Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m² surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice.

Safety and effectiveness of simvastatin in patients 10-17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial in adolescent boys and in girls who were at least 1 year post-menarche. Patients treated with simvastatin had an adverse reaction profile similar to that of patients treated with placebo. **Doses greater than 40 mg have not been studied in this population.** In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls. [See Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Studies (14.2).]

Adolescent females should be counseled on appropriate contraceptive methods while on simvastatin therapy [see Contraindications (4) and Use in Specific Populations (8.1)]. Simvastatin has not been studied in patients younger than 10 years of age, nor in pre-menarchal girls.

8.5 Geriatric Use

Of the 2,423 patients who received simvastatin in Phase III clinical studies and the 10,269 patients in the Heart Protection Study who received simvastatin, 363 (15%) and 5,366 (52%), respectively were \geq 65 years old. In HPS, 615 (6%) were \geq 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Since advanced age (\geq 65 years) is a predisposing factor for myopathy, simvastatin should be prescribed with caution in the elderly. [See Clinical Pharmacology (12.3).]

A pharmacokinetic study with simvastatin showed the mean plasma level of statin activity to be approximately 45% higher in elderly patients between 70-78 years of age compared with patients between 18-30 years of age. In 4S, 1,021 (23%) of 4,444 patients were 65 or older. Lipid-lowering efficacy was at least as great in elderly patients compared with younger patients, and simvastatin significantly reduced total mortality and CHD mortality in elderly patients with a history of CHD. In HPS, 52% of patients were elderly (4,891 patients 65-69 years and 5,806 patients 70 years or older). The relative risk reductions of CHD death, non-fatal MI, coronary and non-coronary revascularization procedures, and stroke were similar in older and younger patients [see Clinical Studies (14.1)]. In HPS, among 32,145 patients entering the active run-in period, there were 2 cases of myopathy/rhabdomyolysis; these patients were aged 67 and 73. Of the 7 cases of myopathy/rhabdomyolysis among 10,269 patients allocated to simvastatin, 4 were aged 65 or more (at baseline), of whom one was over 75. There were no overall differences in safety between older and younger patients in either 4S or HPS.

Because advanced age (\geq 65 years) is a predisposing factor for myopathy, including rhabdomyolysis, simvastatin should be prescribed with caution in the elderly. In a clinical trial of patients treated with simvastatin 80 mg/day, patients \geq 65 years of age had an increased risk of myopathy, including rhabdomyolysis, compared to patients <65 years of age. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]

8.6 Renal Impairment

Caution should be exercised when simvastatin is administered to patients with severe renal impairment. [See Dosage and Administration (2.6).]

8.7 Hepatic Impairment

Simvastatin is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see Contraindications (4) and Warnings and Precautions (5.2)].

10 OVERDOSAGE

Significant lethality was observed in mice after a single oral dose of 9 g/m². No evidence of lethality


was observed in rats or dogs treated with doses of 30 and 100 g/m², respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were emesis and mucoid stools.

A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae. Supportive measures should be taken in the event of an overdose. The dialyzability of simvastatin and its metabolites in man is not known at present.

11 DESCRIPTION

Simvastatin is a lipid-lowering agent that is derived synthetically from a fermentation product of *Aspergillus terreus*. After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed to the corresponding β -hydroxyacid form. This is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.

Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 α ,3 α ,7 β ,8 β (2S*,4S*),-8a β]]. The empirical formula of simvastatin is C₂₅H₃₈O₅ and its molecular weight is 418.57. Its structural formula is:



Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol.

Tablets simvastatin for oral administration contain either 5 mg, 10 mg, 20 mg, 40 mg or 80 mg of simvastatin and the following inactive ingredients: ascorbic acid, citric acid, hydroxypropyl cellulose, hypromellose, iron oxides, lactose, magnesium stearate, microcrystalline cellulose, pregelatinized starch (maize), talc, and titanium dioxide. Butylated hydroxyanisole is added as a preservative.

Simvastatin 10mg, 20mg, and 40 mg contain red and yellow ferric oxide.

Simvastatin 80 mg contains red ferric oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Simvastatin is a prodrug and is hydrolyzed to its active β -hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.

12.2 Pharmacodynamics

Epidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of atherosclerosis and increased

cardiovascular risk. Lowering LDL-C decreases this risk. However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.

12.3 Pharmacokinetics

Simvastatin is a lactone that is readily hydrolyzed *in vivo* to the corresponding β -hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the β -hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.

Following an oral dose of ¹⁴C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus ¹⁴C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (<5%).

Both simvastatin and its β -hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier.

The major active metabolites of simvastatin present in human plasma are the β -hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives. Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. While the recommended therapeutic dose range is 5 to 40 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.

In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age. Clinical study experience in the elderly (n=1522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].

Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by create-nine clearance).

Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.

The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].

Coadministered Drug or Grapefruit Juice	Dosing of Coadministered Drug or Grapefruit Juice	Dosing of Simvastatin	Geometric Mean (Ratio* with / wit coadministered o No Effect = 1.		Jt
				AUC	Cmax
Contraindicated with sin	wastatin [see Contraindications	(4) and Warnings and P	vecautions (5.1)]		111 1111
Telithromycin ^T	200 mg QD for 4 days	80 mg	simvastatin acid ¹	12	15
(annan gan			simvastatin	8.9	5.3
Nelfinavir ⁷	1250 mg BID for 14 days	20 mg QD for 28	simvastatin acid ¹	1.12	0.66
		days	simvastatin	6	6.2
Itraconazole ^T	200 mg QD for 4 days	80 mg	simvastatin acid ²		13.1
Posaconazole	100 mg (oral suspension)	40 mg	simvastatin acid	7.3	9.2
	QD for 13 days		simvastatin	10.3	9.4
	200 mg (oral suspension) QD for 13 days	40 mg	simvastatin acid	8.5	9.5
Gemfibrozil	600 mg BID for 3 days	40 mg	simvastatin acid	2.85	2.18
100000000000000	a state of the sta		simvastatin	1.35	0.91
Avoid grapefruit juice wi	th simvastatin (see Warnings ar	nd Precautions (5.1)]			
Grapefruit Juice ⁵	200 mL of double-strength	60 mg single dose	simvastatin acid	7	1
(high dose)	TID ⁵		simvastatin	16	
Grapefruit Juice ⁹	8 oz (about 237mL) of	20 mg single dose	simvastatin acid	1.3	
(low dose)	single-strength*	8545301	simvastatin	1,9	
Avoid taking with >10 m	g simvastatin, based on clinical	and/or post-marketing ex	perience (see Warning	s and Preca	autions (5.1)
Verapamil SR	240 mg QD Days 1-7 then	80 mg on Day 10	simvastatin acid	2.3	2.4
2002 CONTRACTOR	240 mg BID on Days 8-10		simvastatin	2.5	2.1
Diltiazem	120 mg BID for 10 days	80 mg on Day 10	simvastatin acid	2.69	2.69
Ditiazem	120 mg BID for 14 days	20 mg on Day 14	simvastatin	3.10	2.88
Dronedarone	400 mg BID for 14 days	40 mg QD	simvastatin acid	1.96	2.14
En or revolution in	too ng bib ioi it oays	for 14 days	simvastatin	3.90	3.75
Avoid taking with >20 m	simvastatin, based on clinical i	and/or post-marketing e	perience /see Warning	s and Preca	autions (5.1)
Amiodarone	400 mg QD for 3 days	40 mg on Day 3	simvastatin acid	1.75	1.72
California	400 mg do for o days	40 mg on bay o	simvastatin	1.76	1.79
Amlodipine	10 mg QD x 10 days	80 mg on Day 10	simvastatin acid	1.58	1.56
			sintvastatin	1.77	1.47
Ranolazine SR	1000 mg BID for 7 days	80 mg on Day 1 and Days 6-9	simvastatin acid	2.26	2.28
No dosing adjustments r	equired for the following:				
Fenofibrate	160 mg QD X 14 days	80 mg QD on Days	simvastatin acid	0.64	0.89
		8-14	simvastatin	0.89	0.83
Niacin	2 g single dose	20 mg single dose	simvastatin acid	1.6	1.84
extended-release *			simvastatin	1.4	1.08
Propranolol	80 mg single dose	80 mg single dose	total inhibitor	0.79	↓ from 33.6 to 21.1 ng-eq/m
			active inhibitor	0.79	į from 7.0 to 4. ng eg/m

TABLE 3

Results based on a chemical assay except results with propranolol as indicated. Results could be representative of the following CYP3A4 inhibitors: ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone.

Simvastatin acid refers to the β-hydroxyacid of simvastatin.

The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied. Double-strength: one can of frozen concentrate diluted with one can of water. Grapefruit juice was administered TID for 2 days, and 200 mL together with single dose simvastatin on Day 3. Single-strength: one can of frozen concentrate diluted with 3 cans of water. Grapefruit juice was administered with breakfast for 3 days, and simvastatin was administered in the evening on Day 3.

Because Chinese patients have an increased risk for myopathy with simvastatin coadministered with lipid-modifying doses (≥ 1 gram/day niacin) of niacin-containing products, and the risk is dose-related. Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products [see Warnings and Precautions (5.1) and Drug Interactions (7.4)].

In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.

Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility

In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and midand high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the

liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day.

In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC).

In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC).

A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other statins. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose.

No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an in vitro alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an *in vitro* chromosome aberration study in CHO cells, or an *in vivo* chromosomal aberration assay in mouse bone marrow.

There was decreased fertility in male rats treated with simvastatin for 34 weeks at 25 mg/kg body weight (4 times the maximum human exposure level, based on AUC, in patients receiving 80 mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11 weeks (the entire cycle of spermatogenesis including epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180 mg/kg/day, (which produces exposure levels 22 times higher than those in humans taking 80 mg/day based on surface area, mg/m²), seminiferous tubule degeneration (necrosis and loss of spermatogenesis, spermatocytic degeneration and giant cell formation at 10 mg/kg/day, (approximately 2 times the human exposure, based on AUC, at 80 mg/day). The clinical significance of these findings is unclear.

13.2 Animal Toxicology and/or Pharmacology

CNS Toxicity

Optic nerve degeneration was seen in clinically normal dogs treated with simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma drug levels about 12 times higher than the mean plasma drug level in humans taking 80 mg/day.

A chemically similar drug in this class also produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal ganglion cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose.

CNS vascular lesions, characterized by perivascular hemorrhage and edema, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and necrosis of small vessels were seen in dogs treated with simvastatin at a dose of 360 mg/kg/day, a dose that produced mean plasma drug

levels that were about 14 times higher than the mean plasma drug levels in humans taking 80 mg/day. Similar CNS vascular lesions have been observed with several other drugs of this class.

There were cataracts in female rats after two years of treatment with 50 and 100 mg/kg/day (22 and 25 times the human AUC at 80 mg/day, respectively) and in dogs after three months at 90 mg/kg/day (19 times) and at two years at 50 mg/kg/day (5 times).

14 CLINICAL STUDIES

14.1 Clinical Studies in Adults

Reductions in Risk of CHD Mortality and Cardiovascular Events

In 4S, the effect of therapy with simvastatin on total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this multicenter, randomized, doubleblind, placebo-controlled study, patients were treated with standard care, including diet, and either simvastatin 20-40 mg/day (n=2,221) or placebo (n=2,223) for a median duration of 5.4 years. Over the course of the study, treatment with simvastatin led to mean reductions in total-C, LDL-C and TG of 25%, 35%, and 10%, respectively, and a mean increase in HDL-C of 8%. Simvastatin significantly reduced the risk of mortality by 30% (p=0.0003, 182 deaths in the simvastatin group vs 256 deaths in the placebo group). The risk of CHD mortality was significantly reduced by 42% (p=0.00001, 111 vs 189 deaths). There was no statistically significant difference between groups in non-cardiovascular mortality. Simvastatin significantly decreased the risk of having major coronary events (CHD mortality plus hospital-verified and silent nonfatal myocardial infarction [MI]) by 34% (p<0.00001, 431 vs 622 patients with one or more events). The risk of having a hospital-verified non-fatal MI was reduced by 37%. Simvastatin significantly reduced the risk for undergoing myocardial revascularization procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) by 37% (p<0.00001, 252 vs 383 patients). Simvastatin significantly reduced the risk of fatal plus non-fatal cerebrovascular events (combined stroke and transient ischemic attacks) by 28% (p=0.033, 75 vs 102 patients). Simvastatin reduced the risk of major coronary events to a similar extent across the range of baseline total and LDL cholesterol levels. Because there were only 53 female deaths, the effect of simvastatin on mortality in women could not be adequately assessed. However, simvastatin significantly lessened the risk of having major coronary events by 34% (60 vs 91 women with one or more event). The randomization was stratified by angina alone (21% of each treatment group) or a previous MI. Because there were only 57 deaths among the patients with angina alone at baseline, the effect of simvastatin on mortality in this subgroup could not be adequately assessed. However, trends in reduced coronary mortality, major coronary events and revascularization procedures were consistent between this group and the total study cohort. Additionally, simvastatin resulted in similar decreases in relative risk for total mortality, CHD mortality, and major coronary events in elderly patients (\geq 65 years), compared with younger patients.

The Heart Protection Study (HPS) was a large, multi-center, placebo-controlled, double-blind study with a mean duration of 5 years conducted in 20,536 patients (10,269 on simvastatin 40 mg and 10,267 on placebo). Patients were allocated to treatment using a covariate adaptive method³ which took into account the distribution of 10 important baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients had a mean age of 64 years (range 40-80 years), were 97% Caucasian and were at high risk of developing a major coronary event because of existing CHD (65%), diabetes (Type 2, 26%; Type 1, 3%), history of stroke or other cerebrovascular disease (16%), peripheral vessel disease (33%), or hypertension in males \geq 65 years (6%). At baseline, 3,421 patients (17%) had LDL-C levels below 100 mg/dL, of whom 953 (5%) had LDL-C levels below 80 mg/dL; 7,068 patients (34%) had levels between 100 and 130 mg/dL; and 10,047 patients (49%) had levels greater than 130 mg/dL.

³D.R. Taves, Minimization: a new method of assigning patients to treatment and control groups. Clin.

Pharmacol. Ther. 15 (1974), pp. 443-453


The HPS results showed that simvastatin 40 mg/day significantly reduced: total and CHD mortality; non-fatal MI, stroke, and revascularization procedures (coronary and non-coronary) (see Table 4).

	Summary of	TABLE 4 Heart Protection St	udv Results	
Endpoint	Simvastatin (N=10,269) n (%) [†]	Placebo (N=10,267) n (%) [†]	Risk Reduction (%) (95% CI)	p-Value
Primary		21		
Mortality	1,328 (12.9)	1,507 (14.7)	13 (6-19)	p=0.0003
CHD mortality	587 (5.7)	707 (6.9)	18 (8-26)	p=0.0005
Secondary				
Non-fatal MI	357 (3.5)	574 (5.6)	38 (30-46)	p<0.0001
Stroke	444 (4.3)	585 (5.7)	25 (15-34)	p<0.0001
Tertiary				
Coronary revascularization	513 (5)	725 (7.1)	30 (22-38)	p<0.0001
Peripheral and other non-coronary revascularization	450 (4.4)	532 (5.2)	16 (5-26)	p=0.006

[†] n = number of patients with indicated event

Two composite endpoints were defined in order to have sufficient events to assess relative risk reductions across a range of baseline characteristics (see Figure 1). A composite of major coronary events (MCE) was comprised of CHD mortality and non-fatal MI (analyzed by time-to-first event; 898 patients treated with simvastatin had events and 1,212 patients on placebo had events). A composite of major vascular events (MVE) was comprised of MCE, stroke and revascularization procedures including coronary, peripheral and other non-coronary procedures (analyzed by time-to-first event; 2,033 patients treated with simvastatin had events and 2,585 patients on placebo had events). Significant relative risk reductions were observed for both composite endpoints (27% for MCE and 24% for MVE, p<0.0001). Treatment with simvastatin produced significant relative risk reductions for all components of the composite endpoints. The risk reductions produced by simvastatin in both MCE and MVE were evident and consistent regardless of cardiovascular disease related medical history at study entry (i.e., CHD alone; or peripheral vascular disease, cerebrovascular disease, diabetes or treated hypertension, with or without CHD), gender, age, creatinine levels up to the entry limit of 2.3 mg/dL, baseline levels of LDL-C, HDL-C, apolipoprotein B and A-1, baseline concomitant cardiovascular medications (i.e., aspirin, beta blockers, or calcium channel blockers), smoking status, alcohol intake, or obesity. Diabetics showed risk reductions for MCE and MVE due to simvastatin treatment regardless of baseline HbA_{1c} levels or obesity with the greatest effects seen for diabetics without CHD.





N = number of patients in each subgroup. The inverted biangles are point estimates of the relative risk, with their 95% confidence intervals represented as a line. The area of a biangle is proportional to the number of patients with MVE or MCE in the subgroup relative to the number with MVE or MCE. respectively, in the entire study oppulation. The vertical solid line represents a relative risk of one. The vertical dashed line represents the point estimate of relative risk in the entire study oppulation.

Angiographic Studies

In the Multicenter Anti-Atheroma Study, the effect of simvastatin on atherosclerosis was assessed by quantitative coronary angiography in hypercholesterolemic patients with CHD. In this randomized, double-blind, controlled study, patients were treated with simvastatin 20 mg/day or placebo. Angiograms were evaluated at baseline, two and four years. The co-primary study endpoints were mean change per-patient in minimum and mean lumen diameters, indicating focal and diffuse disease, respectively. Simvastatin significantly slowed the progression of lesions as measured in the Year 4 angiogram by both parameters, as well as by change in percent diameter stenosis. In addition, simvastatin significantly decreased the proportion of patients with new lesions and with new total occlusions.

Modifications of Lipid Profile

Primary Hypercholesterolemia (Fredrickson type lla and llb)

Simvastatin has been shown to be effective in reducing total-C and LDL-C in heterozygous familial and non-familial forms of hyperlipidemia and in mixed hyperlipidemia. Maximal to near maximal response is generally achieved within 4-6 weeks and maintained during chronic therapy.

Simvastatin consistently and significantly decreased total-C, LDL-C, total-C/HDL-C ratio, and LDL-C/HDL-C ratio; simvastatin also decreased TG and increased HDL-C (see Table 5).

	TABLE 5
Mean Response in Patients with Primary	Hyperlipidemia and Combined (mixed) Hyperlipidemia

TREATMENT	N	TOTAL-C	LDL-C	HDL-C	TGI	
Lower Dose Comparative Study ¹						
(Mean % Change at Week 6)						
Simvastatin 5 mg g.p.m.	109	-19	-26 -30	10	-12	
Simvastatin 10 mg g.p.m.	110	-19 -23	-30	10 12	-15	
Scandinavian Simvastatin Survival Study	Ċ					
(Mean % Change at Week 6)						
Placebo	2223	-1	-1	0	-2	
Simvastatin 20 mg q.p.m.	2221	-28	-38	8	-19	
Upper Dose Comparative Study ¹						
(Mean % Change Averaged at Weeks 18	and 24)					
Simvastatin 40 mg g.p.m.	433	-31 -36	-41	9	-18	
Simvastatin 80 mg g.p.m. ¹	664	-36	-47	8	-18 -24	
Multi-Center Combined Hyperlipidemia S	Study#					
(Mean % Change at Week 6)	1111111					
Placebo	125	1	2	3	-4	
Simvastatin 40 mg q.p.m.	123	-25 -31	-29	13	-4 -28 -33	
Simvastatin 80 mg q.p.m.	124	-31	-36	16	-33	

median percent change mean baseline LDL-C 244 mg/dL, and median baseline TG 168 mg/dL mean baseline LDL-C 188 mg/dL and median baseline TG 128 mg/dL mean baseline LDL-C 226 mg/dL, and median baseline TG 156 mg/dL 21% and 36% median reduction in TG in patients with TG < 200 mg/dL, and TG > 200 mg/dL, respectively. Patients with TG > 350 mg/dL were excluded mean baseline LDL-C 156 mg/dL and median baseline TG 391 mg/dL.

Hypertriglyceridemia (Fredrickson type IV)

The results of a subgroup analysis in 74 patients with type IV hyperlipidemia from a 130-patient, double-blind, placebo-controlled, 3-period crossover study are presented in Table 6.

				ffects of Simvastatin in (25 th and 75 th percen	n Type IV Hyperlipidemi: itile) from Baseline†	a	
TREATMENT	N	Total-C	LDL-C	HDL-C	TG	VLDL-C	Non-HDL-C
Placebo	74	+2 (-7, +7)	+1 (-8, +14)	+3 (-3, +10)	-9 (-25, +13)	-7 (-25, +11)	+1 (-9, +8)
Simvastatin 40 mg/day	74	-25 (-34, -19)	-28 (-40, -17)	+11 (+5, +23)	-29 (-43, -16)	-37 (-54, -23)	-32 (-42, -23)
Simvastatin 80 mg/day	74	-32 (-38, -24)	-37 (-46, -26)	+15 (+5, +23)	-34 (-45, -18)	-41 (-57, -28)	-38 (-49, -32)

The median baseline values (mg/dL) for the patients in this study were: total-C = 254, LDL-C = 135, HDL-C = 36, TG = 404, VLDL-C = 83, and non-HDL-C = 215.

Dysbetalipoproteinemia (Fredrickson type lll)

The results of a subgroup analysis in 7 patients with type lll hyperlipidemia (dysbetalipoproteinemia) (apo E2/2) (VLDL-C/TG>0.25) from a 130-patient, double-blind, placebo-controlled, 3-period crossover study are presented in Table 7.

				flects of Simvastatin in Change (min, max) fro		ris .	
REATMENT	N	Total-C	LDL-C + IDL	HDL-C	TG	VLDL-C + IDL	Non-HDL-C
Placebo	7	-8 (-24, +34)	-8 (-27, +23)	-2 (-21, +16)	+4 (-22, +90)	-4 (-28, +78)	-8 (-26, -39)
Simvastatin 40 mg/day	7	-50 (-66, -39)	-50 (-60, -31)	+7 (-8, +23)	-41 (-74, -16)	-58 (-90, -37)	-57 (-72, -44)
Simvastatin 80 mg/day	7	-52 (-55, -41)	-51 (-57, -28)	+7 (-5, +29)	-38 (-58, +2)	-60 (-72, -39)	-59 (-61, -46)

Homozygous Familial Hypercholesterolemia

In a controlled clinical study, 12 patients 15-39 years of age with homozygous familial hypercholesterolemia received simvastatin 40 mg/day in a single dose or in 3 divided doses, or 80 mg/day in 3 divided doses. In 11 patients with reductions in LDL-C, the mean LDL-C changes for the 40- and 80-mg doses were 14% (range 8% to 23%, median 12%) and 30% (range 14% to 46%, median 29%), respectively. One patient had an increase of 15% in LDL-C. Another patient with absent LDL-C receptor function had an LDL-C reduction of 41% with the 80-mg dose.

Endocrine Function

In clinical studies, simvastatin did not impair adrenal reserve or significantly reduce basal plasma cortisol concentration. Small reductions from baseline in basal plasma testosterone in men were observed in clinical studies with simvastatin, an effect also observed with other statins and the bile acid sequestrant cholestyramine. There was no effect on plasma gonadotropin levels. In a placebocontrolled, 12-week study there was no significant effect of simvastatin 80 mg on the plasma testosterone response to human chorionic gonadotropin. In another 24-week study, simvastatin 20-40 mg had no detectable effect on spermatogenesis. In 4S, in which 4,444 patients were randomized to simvastatin 20-40 mg/day or placebo for a median duration of 5.4 years, the incidence of male sexual adverse events in the two treatment groups was not significantly different. Because of these factors, the small changes in plasma testosterone are unlikely to be clinically significant. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.

14.2 Clinical Studies in Adolescents

In a double-blind, placebo-controlled study, 175 patients (99 adolescent boys and 76 post-menarchal girls) 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolemia (HeFH) were randomized to simvastatin (n=106) or placebo (n=67) for 24 weeks (base study). Inclusion in the study required a baseline LDL-C level between 160 and 400 mg/dL and at least one parent with an LDLC level >189 mg/dL. The dosage of simvastatin (once daily in the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40 mg thereafter. In a 24-week extension, 144 patients elected to continue therapy with simvastatin 40 mg or placebo.

Simvastatin significantly decreased plasma levels of total-C, LDL-C, and Apo B (see Table 8). Results from the extension at 48 weeks were comparable to those observed in the base study.

Dosage	Duration	N		Total-C	LDL-C	HDL-C	TG ¹	Apo B
Placebo	24 Weeks	67	% Change from Baseline (95% CI) Mean baseline, mg/dL (SD)	(-2.2, 5.3) 278.6 (51.8)	1.1 (-3.4, 5.5) 211.9 (49)	3.6 (-0.7, 8) 46.9 (11.9)	-3.2 (-11.8, 5.4) 90 (50.7)	-0.5 (-4.7, 3.6) 186.3 (38.1)
Sinvastatin	24 Weeks	106	% Change from Baseline (95% CI) Mean baseline, mg/dL (SD)	-26.5 (-29.6,-23.3) 270.2 (44)	-36.8 (-40.5, -33) 203.8 (41.5)	(4.6, 11.9) 47.7 (9)	-7.9 (-15.8, 0) 78.3 (46)	-32.4 (-35.9, -29) 179.9 (33.8)

1 median percent change

After 24 weeks of treatment, the mean achieved LDL-C value was 124.9 mg/dL (range: 64 to 289 mg/dL) in the simvastatin 40 mg group compared to 207.8 mg/dL (range: 128 to 334 mg/dL) in the placebo group.

The safety and efficacy of doses above 40 mg daily have not been studied in children with HeFH. The long-term efficacy of simvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.

16 HOW SUPPLIED

Simvastatin Tablets USP 5 mg are white to off white, oval, biconvex, film-coated tablets with "B300" debossed on one side and "5" on the other side.

Simvastatin Tablets USP 10 mg are peach to dark peach, oval, biconvex, film-coated tablets with "B301" debossed on one side and "10" on the other side.

Simvastatin Tablets USP 20 mg are orange to dark orange, oval, biconvex, film-coated tablets with "B302" debossed on one side and "20" on the other side.

Simvastatin Tablets USP 40 mg are light pink to pink, oval, biconvex, film-coated tablets with "B303" debossed on one side and "40" on the other side.

Simvastatin Tablets USP 80 mg are dark pink to pink, capsule-shaped, film-coated tablets with "B304" debossed on one side and "80" on the other side.

They are supplied by **State of Florida DOH Central Pharmacy** as follows:

				Source Prod.
NDC	Strength	Quantity/Form	Color	Code
F0000		CO Tableta in a Dlieter		

53008- 0927-2	5 MG	Do Tableis III a Bilster Pack	white to off white	24658-300
53808- 0952-1	40 MG	30 Tablets in a Blister Pack	light pink to pink	24658-303
53808- 1078-2	10 MG	60 Tablets in a Blister Pack	peach to dark peach	24658-301

Storage

Store between 20-25°C (68-77°F).

17 PATIENT COUNSELING INFORMATION

Patients should be advised to adhere to their National Cholesterol Education Program (NCEP)recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel.

Patients should be advised about substances they should not take concomitantly with simvastatin [see Contraindications (4) and Warnings and Precautions (5.1)]. Patients should also be advised to inform other healthcare professionals prescribing a new medication or increasing the dose of an existing medication that they are taking simvastatin.

17.1 Muscle Pain

All patients starting therapy with simvastatin should be advised of the risk of myopathy, including rhabdomyolysis, and told to report promptly any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing simvastatin. **Patients using the 80-mg dose should be informed that the risk of myopathy, including rhabdomyolysis, is increased with use of the 80-mg dose.** The risk of myopathy, including rhabdomyolysis, occurring with use of simvastatin is increased when taking certain types of medication or consuming grapefruit juice. Patients should discuss all medication, both prescription and over the counter, with their healthcare professional.

17.2 Liver Enzymes

It is recommended that liver function tests be performed before the initiation of simvastatin, and thereafter when clinically indicated. All patients treated with simvastatin should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.

17.3 Pregnancy

Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using simvastatin. Discuss future pregnancy plans with your patients, and discuss when to stop taking simvastatin if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking simvastatin and call their healthcare professional.

17.4 Breastfeeding

Women who are breastfeeding should not use simvastatin. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professional

Manufactured by: Blu Caribe Dorado, PR 00646 Manufactured for: Blu Pharmaceuticals, Franklin, KY 42134

1-877-264-0258


This Product was Repackaged By:

State of Florida DOH Central Pharmacy

104-2 Hamilton Park Drive Tallahassee, FL 32304 USA


PACKAGE LABEL

Label Image for **53808-0927 5mg**



PACKAGE LABEL

Label Image for **53808-1078 10mg**



PACKAGE LABEL

Label Image for **53808-0952 40mg**



SIMVASTATIN

Flavor

Contains

simvastatin tablet, fil	m coated						
Product Information	tion						
Product Type		7(NDC:24658-300)					
Route of Administra	tion	ORAL					
Active Ingredien	t/Active Moi	ety					
	Ing	redient Name		Basis of Streng	th Strength		
SIMVASTATIN (UNII:	AGG2FN16EV) (SIMVASTATIN - UNII:AGG2FN1	SEV)	SIMVASTATIN	5 mg		
Inactive Ingredients							
	Ingredient Name Strength						
ASCORBIC ACID (UNII: PQ6CK8PD0R)							
BUTYLATED HYDRO XYANISOLE (UNII: REK4960K2U)							
ANHYDRO US CITRIC ACID (UNII: XF417D3PSL)							
HYPROMELLOSES (UNII: 3NXW29V3WO)							
LACTOSE MONOHYI	DRATE (UNII: EV	VQ57Q8I5X)					
MAGNESIUM STEAR	ATE (UNII: 7009	7M6I30)					
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)							
STARCH, CORN (UNII	: 08232NY3SJ)						
TALC (UNII: 7SEV7J4F	R1U)						
TITANIUM DIO XIDE (UNII: 15FIX9V2J	P)					
ALCOHOL (UNII: 3K9	958V90M)						
POVIDONES (UNII: FZ	989GH94E)						
TRIETHYL CITRATE	TRIETHYL CITRATE (UNII: 8Z96QXD6UM)						
COLLOIDAL SILICO	N DIO XIDE (UN	II: ETJ7Z6 XBU4)					
Product Characte	eristics						
Color							
Shape	hape OVAL (biconvex) Size 6mm						
	•						

Imprint Code

B300;5

#	Item Code	Package Description	Marketi	ng Start Date	Μ	arketing End Date
I ND	DC:53808-0927-2	60 in 1 BLISTER PACK				
	whating Info	mation				
Ma	rketing Info	mation				
	0		graph Citation	Marketing Star	t Date	Marketing End Da
	rketing Info ı Keting Category	mation Application Number or Mono	graph Citation	Marketing Star	t Date	Marketing End Da
	keting Category		graph Citation	Marketing Star 0 1/0 1/20 14	t Date	Marketing End Da

SIMVASTATIN	[
simvastatin tablet, filn	n coated						
Product Informati	on						
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Sour	(e) NDC:53808-0952	(NDC:24658-303)		
Route of Administrati	ion	ORAL					
• ·· • • • ·· ·							
Active Ingredient/		5					
		redient Name		Basis of Strengtl			
SIMVASTATIN (UNII: A	GG2FN16EV) (S	SIMVASTATIN - UNII:AGG2FN16	EV)	SIMVASTATIN	40 mg		
Inactive Ingredien	nts						
inactive ingreater		Ingredient Name			Strength		
ASCORBIC ACID (UNII:	PQ6CK8PD0R	-			0		
BUTYLATED HYDROX	YANISOLE (U	NII: REK4960K2U)					
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)							
HYPROMELLOSES (UNII: 3NXW29V3WO)							
FERRIC O XIDE YELLO	W (UNII: EX43	8O2MRT)					
ISOPROPYL ALCOHO	L (UNII: ND2M	416302)					
LACTOSE MONOHYD	RATE (UNII: EV	VQ57Q8I5X)					
MAGNESIUM STEARATE (UNII: 70097M6I30)							
CELLULOSE, MICROC	RYSTALLINE	(UNII: OP1R32D61U)					
STARCH, CORN (UNII:	O8232NY3SJ)						
TALC (UNII: 7SEV7J4R1	.U)						
TITANIUM DIO XIDE (U	JNII: 15FIX9V2J	P)					
FERRIC OXIDE RED (U	NII: 1K09F3G67	75)					
COLLOIDAL SILICON	DIO XIDE (UN	II: ETJ7Z6XBU4)					
POVIDONES (UNII: FZ9	89GH94E)						
TRIETHYL CITRATE (U	UNII: 8Z96QXD	6UM)					
Product Character	ristics						
	PINK (light pink	to nink)	Score	20	SCOTA		
COLOL	т пис (пgнt ршк	to pink)	Score	110	score		

Flavor	(ex)		ze		14mn	-
			In	print Code		B303	3;40
Contains							
Packaging							
# Item Code	Pac	kage Description	Marketii	ıg Start Date	Ma	rketing	End Date
1 NDC:53808-0952-1		LISTER PACK		0		0	
Marketing Infor	rmation						
Marketing Category		on Number or Monograpl	h Citation	Marketing S	tart Date	Marketi	ing End Date
ANDA	ANDA078034			0 1/0 1/20 14			0
SIMVASTATIN							
simvastatin tablet, film	coated						
Product Informatio	n						
Product T ype		HUMAN PRESCRIPTION DI	RUG Item C	Code (Source)	NDC:53808	3-1078(NI	DC:24658-301
Route of Administratio	n	ORAL					
Active Ingredient/A	Active Moi	ety					
	Ing	redient Name		T	Basis of Str	rength	Strength
	C C	, culcule i vuine		-			Stitligth
SIMVASTATIN (UNII: AG		SIMVASTATIN - UNII:AGG21	FN16EV)		IVASTATIN	0	10 mg
	GG2FN16EV) (5		FN16EV)		IVASTATIN		-
•	GG2FN16EV) (5		FN16EV)		IVASTATIN		-
•	GG2FN16EV) (5		FN16 EV)		IVASTATIN		-
Inactive Ingredient	GG2FN16EV) (\$	SIMVASTATIN - UNII:AGG21 Ingredient Name	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: 1 BUTYLATED HYDROXY	GG2FN16EV) (5 t s PQ6CK8PD0 R Z ANISOLE (U	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U)	FN16EV)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: 1 BUTYLATED HYDROXY	GG2FN16EV) (5 t s PQ6CK8PD0 R Z ANISOLE (U	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNIE I BUTYLATED HYDROXY ANHYDROUS CITRIC AG	GG2FN16EV) (5 SG2FN16EV) (5 S S PQ6CK8PD0R XANISOLE (U CID (UNII: XF4	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) 417D3PSL)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: 1 BUTYLATED HYDROXY ANHYDROUS CITRIC AG HYPROMELLOSES (UN	GG2FN16EV) (S GG2FN16EV) (S S PQ6CK8PD0 R ZANISOLE (U CID (UNII: XF4 II: 3NXW29 V3	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO)	FN16 EV)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNIE: I BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UNI FERRIC OXIDE YELLOV	GG2FN16EV) (SG2FN16EV) (S PQ6CK8PD0R (ANISOLE (U CID (UNII: XF4 II: 3NXW29V3 W (UNII: EX43	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: 1 BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UN FERRIC OXIDE YELLOV ISOPROPYL ALCOHOL	GG2FN16EV) (GG2FN16EV) (S PQ6CK8PD0 R YANISOLE (U CID (UNII: XF4 II: 3NXW29 V3 W (UNII: EX43 J (UNII: ND2M	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: I BUTYLATED HYDROXY ANHYDROUS CITRIC A HYPROMELLOSES (UNI FERRIC OXIDE YELLOV ISOPROPYL ALCOHOI LACTOSE MONOHYDR	GG2FN16EV) (GG2FN16EV) (ANISOLE (U CID (UNII: XF4 II: 3NXW29V3 W (UNII: EX43 L (UNII: ND2M ATE (UNII: EV	Ingredient Name Ingredient Name NII: REK4960K2U) MID REK4960K2U) MO) 802MRT) 416302) VQ57Q8I5X)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNIE I BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UN FERRIC OXIDE YELLOY ISOPROPYL ALCOHOL LACTOSE MONOHYDR MAGNESIUM STEARAT	GG2FN16EV) (GG2FN16EV) (SG2FN16EV) (SG2FN	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: I BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UNI FERRIC OXIDE YELLOV ISOPROPYL ALCOHOI LACTOSE MONOHYDR MAGNESIUM STEARAT CELLULOSE, MICROCH	GG2FN16EV) (GG2FN16EV) (ANISOLE (U CID (UNII: XF4 II: 3NXW29 V3 W (UNII: EX43 L (UNII: ND2M4 ATE (UNII: EV E (UNII: 7009 RYSTALLINE	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNIE I BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UN FERRIC OXIDE YELLOV ISOPROPYL ALCOHOL LACTOSE MONOHYDR MAGNESIUM STEARAT CELLULOSE, MICROCH STARCH, CORN (UNII: O	GQ2FN16EV) (GQ2FN16EV) (SQ2FN16EV) (SQ2FN	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNII: 1 BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UNI FERRIC OXIDE YELLOV ISOPROPYL ALCOHOI LACTOSE MONOHYDR MAGNESIUM STEARAT CELLULOSE, MICROCE STARCH, CORN (UNII: 0 TALC (UNII: 7SEV7J4RIU	GG2FN16EV) (GG2FN16EV) (SG2FN16EV) (SG2FN	Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30) (UNII: OP1R32D61U)	FN16 E V)		IVASTATIN		10 mg
SIMVASTATIN (UNII: AG Inactive Ingredient ASCORBIC ACID (UNII: I BUTYLATED HYDROXY ANHYDROUS CITRIC AG HYPROMELLOSES (UNI FERRIC OXIDE YELLOV ISOPROPYL ALCOHOL LACTOSE MONOHYDR MAGNESIUM STEARAT CELLULOSE, MICROCE STARCH, CORN (UNII: O TALC (UNII: 7SEV7J4R1U TITANIUM DIOXIDE (UN FERRIC OXIDE RED (UN	G2FN16EV) (G2FN16EV) (ANISOLE (U CID (UNII: XF4 II: 3NXW29V3 W (UNII: EX43 L (UNII: ND2M ATE (UNII: EV E (UNII: 7009) RYSTALLINE 08232NY3SJ) J) NII: 15FIX9V2J	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30) (UNII: OP1R32D61U) P)	FN16 E V)		IVASTATIN		10 mg
Inactive Ingredient ASCORBIC ACID (UNIE I BUTYLATED HYDROXY ANHYDROUS CITRIC AC HYPROMELLOSES (UNI FERRIC OXIDE YELLOV ISOPROPYL ALCOHOL LACTOSE MONOHYDR MAGNESIUM STEARAT CELLULOSE, MICROCH STARCH, CORN (UNIE O TALC (UNIE 75EV7J4RIU	GG2FN16EV) (GG2FN16EV) (ANISOLE (U CID (UNII: XF4 II: 3NXW29V3 W (UNII: EX43 L (UNII: ND2M ATE (UNII: EV E (UNII: 7009) RYSTALLINE 08232NY3SJ) J) NII: 15FIX9V2J JII: 1K09F3G6	SIMVASTATIN - UNII:AGG21 Ingredient Name) NII: REK4960K2U) H17D3PSL) WO) 802MRT) 416302) VQ57Q8I5X) 7M6I30) (UNII: OP1R32D61U) P) 75)	FN16 E V)				10 mg

Product Charac	teristi	CS				
Color	ORANG	E (peach to dark peach)	Score	Score		
Shape	OVAL (biconvex)			Size		9 m m
Flavor	Imprint C			Imprint Code		B301;10
Contains						
Packaging						
# Item Code	e	Package Description	Marketin	g Start Date	Marke	eting End Date
1 NDC:53808-1078-2	2	60 in 1 BLISTER PACK				
Marketing In	form	ation				
Marketing Catego	ry Application Number or Monograph Citation		Marketing Start Date		arketing End Date	
ANDA	AN	ANDA078034 1		11/0 1/20 14		

Labeler - State of Florida DOH Central Pharmacy (829348114)

Establishment

Name	Address	ID/FEI	Business Operations
State of Florida DOH Central Pharmacy		829348114	repack(53808-0927, 53808-0952, 53808-1078)

Revised: 1/2015

State of Florida DOH Central Pharmacy